Company intelligence / Profile preview

Advent Therapeutics

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Advent Therapeutics has developed a proprietary stabilized retinol palmitate drug for neonatal lung therapy; secured a $3 million NIH grant, completing manufacturing scale-up, with plans to make products commercially available for injection by late 2024. Inhaled formulations are in advanced development for broader acute lung indications. No published Phase 2/3 trial results for other indications as of 2024

Therapeutic areas: OphthalmologyInfectious DiseasesPulmonology
Modalities: Small moleculeVitaminBiologic
Industry: Biotech

Partnerships

Pace® Analytical Life Sciences (CDMO)dsm-firmenich (API supply and regulatory)

Beyond the preview

Go deeper on Advent Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advent Therapeutics.

Explore the full profile